vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Claritev Corp (CTEV). Click either name above to swap in a different company.
Claritev Corp is the larger business by last-quarter revenue ($246.6M vs $191.2M, roughly 1.3× Axsome Therapeutics, Inc.). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (57.4% vs 6.2%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs 2.5%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
AXSM vs CTEV — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $191.2M | $246.6M |
| Net Profit | — | $-80.6M |
| Gross Margin | — | — |
| Operating Margin | -33.1% | -3.1% |
| Net Margin | — | -32.7% |
| Revenue YoY | 57.4% | 6.2% |
| Net Profit YoY | — | 41.6% |
| EPS (diluted) | — | $-4.88 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $191.2M | — | ||
| Q4 25 | $196.0M | $246.6M | ||
| Q3 25 | $171.0M | $246.0M | ||
| Q2 25 | $150.0M | $241.6M | ||
| Q1 25 | $121.5M | $231.3M | ||
| Q4 24 | $118.8M | $232.1M | ||
| Q3 24 | $104.8M | $230.5M | ||
| Q2 24 | $87.2M | $233.5M |
| Q1 26 | — | — | ||
| Q4 25 | $-28.6M | $-80.6M | ||
| Q3 25 | $-47.2M | $-69.8M | ||
| Q2 25 | $-48.0M | $-62.6M | ||
| Q1 25 | $-59.4M | $-71.3M | ||
| Q4 24 | $-74.9M | $-138.0M | ||
| Q3 24 | $-64.6M | $-391.4M | ||
| Q2 24 | $-79.3M | $-576.7M |
| Q1 26 | -33.1% | — | ||
| Q4 25 | -13.8% | -3.1% | ||
| Q3 25 | -27.0% | 4.1% | ||
| Q2 25 | -24.5% | 6.9% | ||
| Q1 25 | -46.9% | 4.2% | ||
| Q4 24 | -61.1% | -17.8% | ||
| Q3 24 | -59.8% | -146.7% | ||
| Q2 24 | -89.5% | -224.4% |
| Q1 26 | — | — | ||
| Q4 25 | -14.6% | -32.7% | ||
| Q3 25 | -27.6% | -28.4% | ||
| Q2 25 | -32.0% | -25.9% | ||
| Q1 25 | -48.9% | -30.8% | ||
| Q4 24 | -63.1% | -59.4% | ||
| Q3 24 | -61.7% | -169.8% | ||
| Q2 24 | -91.0% | -247.0% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.55 | $-4.88 | ||
| Q3 25 | $-0.94 | $-4.23 | ||
| Q2 25 | $-0.97 | $-3.81 | ||
| Q1 25 | $-1.22 | $-4.38 | ||
| Q4 24 | $-1.54 | $-8.49 | ||
| Q3 24 | $-1.34 | $-24.25 | ||
| Q2 24 | $-1.67 | $-35.78 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $305.1M | $16.8M |
| Total DebtLower is stronger | $70.0M | $4.6B |
| Stockholders' EquityBook value | — | $-173.9M |
| Total Assets | $713.6M | $4.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $305.1M | — | ||
| Q4 25 | $322.9M | $16.8M | ||
| Q3 25 | $325.3M | $39.2M | ||
| Q2 25 | $303.0M | $56.4M | ||
| Q1 25 | $300.9M | $23.1M | ||
| Q4 24 | $315.4M | $16.8M | ||
| Q3 24 | $327.3M | $86.6M | ||
| Q2 24 | $315.7M | $48.8M |
| Q1 26 | $70.0M | — | ||
| Q4 25 | — | $4.6B | ||
| Q3 25 | — | $4.5B | ||
| Q2 25 | — | $4.5B | ||
| Q1 25 | — | $4.5B | ||
| Q4 24 | — | $4.5B | ||
| Q3 24 | — | $4.5B | ||
| Q2 24 | — | $4.5B |
| Q1 26 | — | — | ||
| Q4 25 | $88.3M | $-173.9M | ||
| Q3 25 | $73.7M | $-101.8M | ||
| Q2 25 | $73.1M | $-39.9M | ||
| Q1 25 | $53.2M | $14.8M | ||
| Q4 24 | $57.0M | $84.0M | ||
| Q3 24 | $92.9M | $207.6M | ||
| Q2 24 | $102.9M | $603.4M |
| Q1 26 | $713.6M | — | ||
| Q4 25 | $689.8M | $4.9B | ||
| Q3 25 | $669.3M | $5.0B | ||
| Q2 25 | $639.8M | $5.1B | ||
| Q1 25 | $596.7M | $5.1B | ||
| Q4 24 | $568.5M | $5.2B | ||
| Q3 24 | $561.5M | $5.3B | ||
| Q2 24 | $548.2M | $5.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 304.87× | ||
| Q4 24 | — | 53.67× | ||
| Q3 24 | — | 21.73× | ||
| Q2 24 | — | 7.48× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $66.3M |
| Free Cash FlowOCF − Capex | — | $36.4M |
| FCF MarginFCF / Revenue | — | 14.8% |
| Capex IntensityCapex / Revenue | — | 12.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-12.3M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $66.3M | ||
| Q3 25 | $1.0M | $19.9M | ||
| Q2 25 | $-32.4M | $61.2M | ||
| Q1 25 | $-43.4M | $-30.1M | ||
| Q4 24 | $-26.2M | $-33.4M | ||
| Q3 24 | $-18.6M | $72.8M | ||
| Q2 24 | $-30.1M | $18.5M |
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $36.4M | ||
| Q3 25 | $988.0K | $-16.3M | ||
| Q2 25 | $-32.4M | $36.6M | ||
| Q1 25 | $-43.7M | $-68.9M | ||
| Q4 24 | $-26.2M | $-63.8M | ||
| Q3 24 | $-18.7M | $41.1M | ||
| Q2 24 | $-30.2M | $-7.0M |
| Q1 26 | — | — | ||
| Q4 25 | -9.6% | 14.8% | ||
| Q3 25 | 0.6% | -6.6% | ||
| Q2 25 | -21.6% | 15.2% | ||
| Q1 25 | -36.0% | -29.8% | ||
| Q4 24 | -22.1% | -27.5% | ||
| Q3 24 | -17.9% | 17.8% | ||
| Q2 24 | -34.6% | -3.0% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 12.1% | ||
| Q3 25 | 0.0% | 14.7% | ||
| Q2 25 | 0.0% | 10.2% | ||
| Q1 25 | 0.3% | 16.8% | ||
| Q4 24 | 0.0% | 13.1% | ||
| Q3 24 | 0.1% | 13.8% | ||
| Q2 24 | 0.1% | 10.9% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
CTEV
Segment breakdown not available.
